Axalimogene filolisbac clinical trials
Also written ADXS11-001.
How each study uses axalimogene filolisbac is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 3
Advaxis, Inc. (5) · Andrew Sikora (1) · Gynecologic Oncology Group (1) · University of Liverpool (1)
Studies
Open first, then newest update. How each study uses axalimogene filolisbac is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical CancerCompletedPhase 1Advaxis, Inc.NCT02164461Written as Axalimogene filolisbac
- A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction ChemotherapyWithdrawnPhase 2Advaxis, Inc.NCT02531854Written as ADXS11-001
- A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal CanalCompletedPhase 2Advaxis, Inc.NCT02399813Written as Axalimogene filolisbac
- Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical CancerTerminatedPhase 3Advaxis, Inc.NCT02853604Written as ADXS11-001
- ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal CancerCompletedPhase 2Andrew SikoraNCT02002182Written as ADXS11-001 (ADXS-HPV)
- Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical CancerCompletedPhase 2Gynecologic Oncology GroupNCT01266460Written as Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001
- An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+TerminatedPhase 2Advaxis, Inc.NCT01116245Written as ADXS11-001 (Lm-LLO-E7)
- Safety Study of Recombinant Listeria Monocytogenes(Lm)Based Vaccine Virus Vaccine to Treat Oropharyngeal CancerTerminatedPhase 1University of LiverpoolNCT01598792Written as ADXS11-001
Given beside what is tested · 1 — axalimogene filolisbac is usual care or a partner of the new treatment
Codes
What other systems call axalimogene filolisbac · ClinicalTrials.gg INT017425
- UNII (FDA) NY7PTD1862AXALIMOGENE FILOLISBACOne source FDA
- NCI Thesaurus C74595Axalimogene FilolisbacOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NY7PTD1862 | AXALIMOGENE FILOLISBAC | One source FDA |
| NCI Thesaurus | C74595 | Axalimogene Filolisbac | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.